ALLR

$1.13+15.58%visit website

Allarity Therapeutics, Inc.

Market Cap

$18M

Live price × SEC shares (Aug 14, 2026)

Sector

Health Care

Industry

Biotechnology

Beta (raw)

0.26

51mo monthly vs SPY

P/E (TTM)

N/M

TTM to Jun 2026 · negative earnings

P/S (TTM)

—

Mkt cap / TTM revenue

P/B

5.1

Mkt cap / shareholders' equity

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q3 FY2025 Sep 30, 2025	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Revenue			25.0	0.0
Research & development	1,203	1,674	1,297	1,345	5,519
Total operating expenses	2,518	3,238	2,713	2,671	11,140
Operating income	(2,518)	(2,918)	(2,688)	(2,671)	(10,795)
Interest expense	57	59	229	719	1,064
Pretax income	(2,806)	(3,373)
Income tax	0.00	0.00
Net income	(2,806)	(3,373)	(2,750)	(3,405)	(12,334)
EPS (basic) ($)	(0.19)		(0.17)	(0.21)	—
Weighted avg. shares (basic)	14,740		15,969	15,911

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 14, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 20 more quarters, back to Sep 2020, with Tormere Pro.

Corporate Events (8-K)

2 filings in 12 months · 1 with priority itemsFull history →

Filed	Items	Filing
Nov 2, 2026 accepted 8:00 AM ET	1.01Material agreement8.01Other events	Document SEC ↗
Oct 30, 2026 accepted 4:05 PM ET	1.02Agreement terminated	Document SEC ↗